|
1
|
Perera ND and Mansfield AS: The evolving
therapeutic landscape for malignant pleural mesothelioma. Curr
Oncol Rep. 24:1413–1423. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sinn K, Mosleh B and Hoda MA: Malignant
pleural mesothelioma: Recent developments. Curr Opin Oncol.
33:80–86. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delgermaa V, Takahashi K, Park EK, Le GV,
Hara T and Sorahan T: Global mesothelioma deaths reported to the
world health organization between 1994 and 2008. Bull World Health
Organ. 89:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rapisarda V, Ledda C, Migliore M, Salemi
R, Musumeci A, Bracci M, Marconi A, Loreto C and Libra M: FBLN-3 as
a biomarker of pleural plaques in workers occupationally exposed to
carcinogenic fibers: A pilot study. Future Oncol. 11:35–37. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rapisarda V, Broggi G, Caltabiano R,
Lombardo C, Castorina S, Trovato A, Ledda C, Filetti V and Loreto
C: ATG7 immunohistochemical expression in malignant pleural
mesothelioma. A preliminary report. Histol Histopathol.
36:1301–1308. 2021.PubMed/NCBI
|
|
6
|
Broggi G, Angelico G, Filetti V, Ledda C,
Lombardo C, Vitale E, Rapisarda V, Loreto C and Caltabiano R:
Immunohistochemical expression of serine and arginine-rich splicing
factor 1 (SRSF1) in fluoro-edenite-induced malignant mesothelioma:
A preliminary study. Int J Environ Res Public Health. 18:62492021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Filetti V, Vitale E, Broggi G, Hagnäs MP,
Candido S, Spina A and Lombardo C: Update of in vitro, in vivo and
ex vivo fluoro-edenite effects on malignant mesothelioma: A
systematic review (Review). Biomed Rep. 13:602020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ledda C, Loreto C, Pomara C, Rapisarda G,
Fiore M, Ferrante M, Bracci M, Santarelli L, Fenga C and Rapisarda
V: Sheep lymph-nodes as a biological indicator of environmental
exposure to fluoro-edenite. Environ Res. 147:97–101. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Filetti V, Loreto C, Falzone L, Lombardo
C, Cannizzaro E, Castorina S, Ledda C and Rapisarda V: Diagnostic
and prognostic value of three microRNAs in environmental
asbestiform fibers-associated malignant mesothelioma. J Pers Med.
11:12052021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paoletti L, Batisti D, Bruno C, Di Paola
M, Gianfagna A, Mastrantonio M, Nesti M and Comba P: Unusually high
incidence of malignant pleural mesothelioma in a town of eastern
Sicily: An epidemiological and environmental study. Arch Environ
Health. 55:392–398. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Comba P, Gianfagna A and Paoletti L:
Pleural mesothelioma cases in Biancavilla are related to a new
fluoro-edenite fibrous amphibole. Arch Environ Health. 58:229–232.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Grosse Y, Loomis D, Guyton KZ,
Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L,
Guha N, Scoccianti C, Mattock H, et al: Carcinogenicity of
fluoro-edenite, silicon carbide fibres and whiskers, and carbon
nanotubes. Lancet Oncol. 15:1427–1428. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H, Kong Q, Wang J, Jiang Y and Hua
H: Complex roles of cAMP-PKA-CREB signaling in cancer. Exp Hematol
Oncol. 9:322020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jackson EK: The 2′,3′-cAMP-adenosine
pathway. Am J Physiol Renal Physiol. 301:F1160–F1167. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Broggi G, Lo Giudice A, Di Mauro M,
Pricoco E, Piombino E, Ferro M, Caltabiano R, Morgia G and Russo
GI: Insulin signaling, androgen receptor and PSMA
immunohistochemical analysis by semi-automated tissue microarray in
prostate cancer with diabetes (DIAMOND study). Transl Res.
238:25–35. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Broggi G, Lo Giudice A, Di Mauro M,
Asmundo MG, Pricoco E, Piombino E, Caltabiano R, Morgia G and Russo
GI: SRSF-1 and microvessel density immunohistochemical analysis by
semi-automated tissue microarray in prostate cancer patients with
diabetes (DIAMOND study). Prostate. 81:882–892. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Galateau-Salle F, Churg A, Roggli V and
Travis WD; World Health Organization Committee For Tumors Of The
Pleura, : The 2015 world health organization classification of
tumors of the pleura: Advances since the 2004 classification. J
Thorac Oncol. 11:142–154. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Massimi M, Ragusa F, Cardarelli S and
Giorgi M: Targeting cyclic AMP signalling in hepatocellular
carcinoma. Cells. 8:15112019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Massimi M, Cardarelli S, Galli F, Giardi
MF, Ragusa F, Panera N, Cinque B, Cifone MG, Biagioni S and Giorgi
M: Increase of intracellular cyclic AMP by PDE4 inhibitors affects
HepG2 cell cycle progression and survival. J Cell Biochem.
118:1401–1411. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tonucci FM, Almada E, Borini-Etichetti C,
Pariani A, Hidalgo F, Rico MJ, Girardini J, Favre C, Goldenring JR,
Menacho-Marquez M and Larocca MC: Identification of a CIP4 PKA
phosphorylation site involved in the regulation of cancer cell
invasiveness and metastasis. Cancer Lett. 461:65–77. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen TC, Hinton DR, Zidovetzki R and
Hofman FM: Up-regulation of the cAMP/PKA pathway inhibits
proliferation, induces differentiation, and leads to apoptosis in
malignant gliomas. Lab Invest. 78:165–174. 1998.PubMed/NCBI
|
|
22
|
Moon EY, Lee GH, Lee MS, Kim HM and Lee
JW: Phosphodiesterase inhibitors control A172 human glioblastoma
cell death through cAMP-mediated activation of protein kinase A and
Epac1/Rap1 pathways. Life Sci. 90:373–380. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cohen JR, Resnick DZ, Niewiadomski P, Dong
H, Liau LM and Waschek JA: Pituitary adenylyl cyclase activating
polypeptide inhibits gli1 gene expression and proliferation in
primary medulloblastoma derived tumor sphere cultures. BMC Cancer.
10:6762010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ge X, Milenkovic L, Suyama K, Hartl T,
Purzner T, Winans A, Meyer T and Scott MP: Phosphodiesterase 4D
acts downstream of Neuropilin to control Hedgehog signal
transduction and the growth of medulloblastoma. Elife.
4:e070682015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Neary CL, Nesterova M, Cho YS, Cheadle C,
Becker KG and Cho-Chung YS: Protein kinase A isozyme switching:
Eliciting differential cAMP signaling and tumor reversion.
Oncogene. 23:8847–8856. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pollack A, Bae K, Khor LY, Al-Saleem T,
Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU and
Sandler HM: The importance of protein kinase A in prostate cancer:
Relationship to patient outcome in radiation therapy oncology group
trial 92-02. Clin Cancer Res. 15:5478–5484. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kok M, Zwart W, Holm C, Fles R, Hauptmann
M, Veer LJ, Wessels LF, Neefjes J, Stål O, Linn SC, et al:
PKA-induced phosphorylation of ERα at serine 305 and high PAK1
levels is associated with sensitivity to tamoxifen in ER-positive
breast cancer. Breast Cancer Res Treat. 125:1–12. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moody SE, Schinzel AC, Singh S, Izzo F,
Strickland MR, Luo L, Thomas SR, Boehm JS, Kim SY, Wang ZC and Hahn
WC: PRKACA mediates resistance to HER2-targeted therapy in breast
cancer cells and restores anti-apoptotic signaling. Oncogene.
34:2061–2071. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shukla A, Bosenberg MW, MacPherson MB,
Butnor KJ, Heintz NH, Pass HI, Carbone M, Testa JR and Mossman BT:
Activated cAMP response element binding protein is overexpressed in
human mesotheliomas and inhibits apoptosis. Am J Pathol.
175:2197–2206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stoppoloni D, Salvatori L, Biroccio A,
D'Angelo C, Muti P, Verdina A, Sacchi A, Vincenzi B, Baldi A and
Galati R: Aromatase inhibitor exemestane has antiproliferative
effects on human mesothelioma cells. J Thorac Oncol. 6:583–591.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Nuvoli B and Galati R: Cyclooxygenase-2,
epidermal growth factor receptor, and aromatase signaling in
inflammation and mesothelioma. Mol Cancer Ther. 12:844–852. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nuvoli B, Germoni S, Morosetti C, Santoro
R, Cortese G, Masi S, Cordone I and Galati R: Exemestane blocks
mesothelioma growth through downregulation of cAMP, pCREB and CD44
implicating new treatment option in patients affected by this
disease. Mol Cancer. 13:692014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Q, Wang W, Yamada T, Matsumoto K, Sakai
K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, et al: Pleural
mesothelioma instigates tumor-associated fibroblasts to promote
progression via a malignant cytokine network. Am J Pathol.
179:1483–1493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marino FZ, Corte CM, Ciaramella V, Erra S,
Ronchi A, Fiorelli A, Vicidomini G, Santini M, Scognamiglio G,
Morgillo F, et al: AXL and MET tyrosine kinase receptors
co-expression as a potential therapeutic target in malignant
pleural mesothelioma. J Pers Med. 12:19932022. View Article : Google Scholar
|
